That information that you showed is impressive but in there,
There is also the focusing from the many formulas in pre-clinical tests, to one, FLUCIDE.
Then SUPer FLUCIDE, ORAL FLUCIDE and INTRAVENIOUS FLUCIDE for immunocompromised patients in hospitals.
Dc Seymour has stated he has a lot of colleages that work in/with immunocompromised patients and they had been asking him to do something for those patients. So he did.
The immunocompromised FLUCIDE could bring about an ORPHAN DESIGNATION for FLUCIDE and NNVC that could be worth a few hundred million dollars and faster results from the FDA.
Then that to the FDA.
Then with ORAL FLUCIDE or Intravenious FLUCIDE?
Then the manufacturing stringency came up.
Add that up with the SMALL COMPANY EFFECTS and here we are in 2013 with a new medical platform now working on TOX studies.
The amount of red tape was not anticipated fully.
No one notes any counter intentions to NNVC and FLUCIDE from anywhere so far.
Market Data 
Markets 
AI
